Abstract Number: 0004 • ACR Convergence 2020
The Impact of the COVID-19 Pandemic on Patients with Chronic Rheumatic Diseases: A Study in 15 Arab Countries
Background/Purpose: To evaluate the impact of the Coronavirus Disease 2019 pandemic (COVID-19) on the access to rheumatology care for patients with chronic rheumatic diseases in…Abstract Number: 0028 • ACR Convergence 2020
Pain in the Time of Corona: Impact of COVID 19 Outbreak on Fibromyalgia Patients
Background/Purpose: Fibromyalgia is a chronic pain disorder, characterized by abnormal pain processing in the central nervous system. Acute or chronic stress may trigger or aggravate…Abstract Number: 0465 • ACR Convergence 2020
The COVID-19 Pandemic and Its Effect on Patients with Chronic Rheumatologic Disease Regarding the Value of Vaccination Recommendations
Background/Purpose: Vaccinations are an important component of care in rheumatology as many patients are immunocompromised by treatment therapies. Patients are sometimes reticent to receive recommended…Abstract Number: 0610 • ACR Convergence 2020
Change in Utilization of Outpatient Services at US Community Rheumatology Practices During COVID-19 Outbreak
Background/Purpose: Patients (pts) with autoimmune diseases managed by rheumatologists represent vulnerable population with risk of serious complications if exposed to novel coronavirus SARS-CoV2. The first…Abstract Number: 0814 • ACR Convergence 2020
“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic
Background/Purpose: During the COVID-19 pandemic, rapid guidelines by the National Institute for Health and Care Excellence (NICE) in the United Kingdom[1] recommended consideration of switching…Abstract Number: 1477 • ACR Convergence 2020
Adherence in Patients with Chronic Rheumatic Diseases Treated with Biological and Synthetic Targeted Therapies During COVID-19 Pandemic
Background/Purpose: Adherence to treatments for chronic rheumatic diseases is influenced by many factors, including the patient's belief in the development of adverse effects such as…Abstract Number: 0006 • ACR Convergence 2020
Race/ethnicity Is Associated with Poor Health Outcomes Amongst Rheumatic Disease Patients Diagnosed with COVID-19 in the US: Data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry
Background/Purpose: Individuals with rheumatic disease, particularly those on immunosuppressive medications, have a higher risk of developing severe infections. However, whether these patients experience more severe…Abstract Number: 0050 • ACR Convergence 2020
Demographic Disparities in the Medically Underserved Populations of Southern California: A Rheumatology Cohort of Cytokine Release Syndrome Patients Due to COVID-19
Background/Purpose: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the present coronavirus disease (COVID-19) pandemic. Multiple epidemiologic reports across the country show…Abstract Number: 0466 • ACR Convergence 2020
Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases living in COVID-19 “hot spots” may have modified their immunomodulatory…Abstract Number: 0613 • ACR Convergence 2020
Modeling the Effects of Covid-19 Protective Behaviors and Healthcare Delivery on the Health of Patients with Rheumatic Disease
Background/Purpose: COVID-19 has caused global disruptions in the management of chronic illnesses. The extent to which patients with rheumatic disease have been affected by COVID-19…Abstract Number: 0949 • ACR Convergence 2020
SLAMF7 Engagement Drives Monocyte Super-Activation in Acute and Chronic Inflammation
Background/Purpose: Monocytes orchestrate immune responses that protect against microbes but can also drive pathological inflammation and autoimmune disease. Monocytes are thought to be activated primarily…Abstract Number: 1478 • ACR Convergence 2020
A Multidisciplinary Registry of Patients with Autoinmune and Immune-Mediated Diseases with Symptomatic COVID-19 Infection from a Single Center
Background/Purpose: National health authorities reported a prevalence of SARS-CoV-2 infection around 7% of the general population in Barcelona county (1). A recent report focused on…Abstract Number: 0007 • ACR Convergence 2020
Antimalarial Drug Shortages During the COVID-19 Pandemic: Results from the Global Rheumatology Alliance Patient Experience Survey
Background/Purpose: Early in the COVID-19 pandemic, hydroxychloroquine and chloroquine were empirically promoted and used for treatment and prevention of SARS-CoV-2 infection. The repurposing of these…Abstract Number: 0051 • ACR Convergence 2020
COVID-Related Distress and Mental Health in Adult Rheumatology Patients During the COVID-19 Pandemic
Background/Purpose: The novel coronavirus disease 2019 (COVID-19) pandemic has significantly affected all aspects of society, especially in the epicenters of New York City (NYC) and…Abstract Number: 0467 • ACR Convergence 2020
Incidence of COVID-19 in Patients Treated with Infliximab Compared to Patients Treated with Rituximab
Background/Purpose: The prevalence of anti-SARS-CoV-2 IgG infection was estimated at 9.7% in the Geneva population end of April 2020. (1) Immunosuppressed patients may be at…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 38
- Next Page »